Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study

Laura Ferrè, Arturo Nuara, Giulia Pavan, Marta Radaelli, Lucia Moiola, Mariaemma Rodegher, Bruno Colombo, Ignacio Juan Keller Sarmiento, Vittorio Martinelli, Letizia Leocani, Filippo Martinelli Boneschi, Giancarlo Comi, Federica Esposito

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple sclerosis (MS) patients frequently suffer from limb spasticity and pain despite antispastic treatments. To investigate nabiximols efficacy and safety in a real-world monocentric Italian cohort, the following data were collected at baseline, week 4, 14 and 48: Ambulation Index (AI), 10-min walking test (10MWT), combined Modified Ashworth scale (cMAS), scores at numerical rating scale for spasticity (sNRS) and pain (pNRS). Responder status was defined as a ≥20 % reduction in sNRS after 4 weeks of treatment. 144 MS patients (123 progressive and 21 relapsing-remitting) complaining of moderate-to-severe spasticity (mean sNRS: 7.5) were included: 138 (95.8 %) completed the first month of therapy and were classified as follows—23.2 % were non-responders, 5.1 % were responders but discontinued treatment due to side effects, 71.7 % were responders with a mean 32 % reduction in sNRS (p 

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalNeurological Sciences
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • Multiple sclerosis
  • Nabiximols
  • Pain
  • Spasticity

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint

Dive into the research topics of 'Efficacy and safety of nabiximols (Sativex<sup>®</sup>) on multiple sclerosis spasticity in a real-life Italian monocentric study'. Together they form a unique fingerprint.

Cite this